CLARITY-AD lecanemab eligibility required APOE genotyping with specific dosing protocols for APOE4 homozygotes after early ARIA-E rates exceeded 25% in that subgroup; bapineuzumab APOE4 ARIA-E precedent informed design.

Evidence span

CLARITY-AD lecanemab eligibility required APOE genotyping with specific dosing protocols for APOE4 homozygotes after early ARIA-E rates exceeded 25% in that subgroup; bapineuzumab APOE4 ARIA-E precedent informed design.

Method & conditions

Evidence type

observational

Method

manual state transition

Species

Homo sapiens

Conditions

Eisai CLARITY-AD (NCT03887455), APOE-stratified safety reporting.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required